



# BSHT Annual Meeting

Thursday 8 – Friday 9 November 2018

The Slate, University of Warwick, Coventry CV4 7AL

[www.bsht.org.uk](http://www.bsht.org.uk)

## FINAL PROGRAMME

BSHT Meetings Ltd | Company no. 4507462 | VAT No. 925 0066 48  
Registered Office: Stanbridge Associates Ltd, 94 West Parade, Lincoln LN1 1JZ

### PROGRAMME – Thursday 8 November

07:00 – 08:00	Breakfast ( <i>Radcliffe House residents only</i> )	<i>Radcliffe Dining Room</i>
09:30 – 10:20	Registration, Refreshments + networking	<i>The Slate</i>
10:20 – 10:30	<b>Welcome + Introduction</b> <i>Jim CRAWLEY</i>	
10:20 – 12:20	<b>SESSION ONE: Plenary 1 and Oral Communications 1</b>	
	<i>Co-chairs: Josefin AHNSTROM &amp; Yotis SENIS</i>	
10:30 – 11:00	<b><i>Profibrinolytic properties of platelets</i></b> <i>Nikki MUTCH</i> (Aberdeen)	
11:00 – 11:05	Discussion	
	<b>Oral Communications 1</b>	
11:05 – 11:15	1 CRYSTAL STRUCTURES OF THE RECOMBINANT $\beta$ -FACTOR XIIa PROTEASE WITH BOUND PRO-ARG AND THR-ARG SUBSTRATE MIMETICS <i>Monika PATHAK, Rosa Manna and Jonas Emsley</i> Centre for Biomolecular Sciences, School of Pharmacy, University of Nottingham, UK	
11:15 – 11:20	Discussion	
11:20 – 11:30	2 CHARACTERISATION OF A NOVEL GPIIb/IIIa KNOCKIN MOUSE THAT LACKS THE LAST 24 AMINO ACIDS OF ITS INTRACELLULAR DOMAIN <i>Isabelle I. SALLES-CRAWLEY, Adela Constantinescu-Bercu, Kevin J Woollard &amp; James TB Crawley</i> Centre for Haematology, Hammersmith Hospital Campus, Imperial College London, London, UK	
11:30 – 11:35	Discussion	
11:35 – 11:45	3 EFFICACY AND SAFETY OF PROTHROMBIN COMPLEX CONCENTRATE IN PATIENTS TREATED WITH RIVAROXABAN OR APIXABAN COMPARED TO WARFARIN PRESENTING WITH MAJOR BLEEDING <i>Deepa RJ ARACHCHILLAGE<sup>1,2</sup>, Sharon Alavian<sup>1</sup>, Jess Griffin<sup>1</sup>, Kamala Gurung<sup>1</sup>, Richard Szydlo<sup>1</sup>, Nilanthi Karawitige<sup>1</sup>, Mike Laffan<sup>1,2</sup></i> <sup>1</sup> Department of Haematology, Imperial College Healthcare NHS Trust, London, UK <sup>2</sup> Department of Haematology, Imperial College London, London, UK	
11:45 – 11:50	Discussion	
11:50 – 12:00	4 WHAT PHYSIOLOGICAL SURFACE IS RESPONSIBLE FOR THE THROMBIN FEEDBACK LOOP ON FACTOR XI? <i>Beth A. WEBB<sup>1</sup>, O. M. Posada<sup>1</sup>, C. Wilson<sup>1</sup>, J. Ahnström<sup>2</sup>, J. H. Morrissey<sup>3</sup> and H. Philippou<sup>1</sup></i> <sup>1</sup> LICAMM, University of Leeds, Leeds, UK <sup>2</sup> Faculty of Medicine, Imperial College London, London, UK <sup>3</sup> Department of Biological Chemistry, Medical School, University of Michigan, Michigan, USA	
12:00 – 12:05	Discussion	

12:05 – 12:15	5 TUMOUR-ASSOCIATED TF-mRNA MAY BE PREDICTIVE OF THE RISK OF PULMONARY EMBOLISM (PE) IN GASTROINTESTINAL CANCER PATIENTS <i>Naima E. BENELHAJ<sup>1</sup>, Camille Ettelaie<sup>2</sup>, Miriam J Johnson<sup>1</sup>, Justin Cooke<sup>3</sup>, Anthony Maraveyas<sup>1</sup></i> <sup>1</sup> Division of Cancer-Hull York Medical School, University of Hull, Cottingham Road, Hull, HU6 7RX, UK, <sup>2</sup> Biomedical Section, School of Life Sciences, University of Hull, Cottingham Road, Hull, HU6 7RX, UK. <sup>3</sup> Department of Pathology, Hull Royal Infirmary, Hull and East Yorkshire NHS Trust, Anlaby Road, Hull, HU3 2JZ
12:15 – 12:20	Discussion
12:20 – 13:20	Lunch, networking + exhibition
13:20 – 15:10	<b>SESSION TWO: Plenary 2 and Scientists-in-Training Session</b>
	<i>Co-chairs: Robert ARIENS &amp; Neil MORGAN</i>
13:20 – 13:50	<b>Tyrosine phosphatases: critical regulators of platelet production and function</b> <i>Yotis SENIS</i> (Birmingham)
13:50 – 13:55	Discussion
	<b>Scientists-in-Training Session</b>
13:55 – 14:05	Scientist in Training 1 IDENTIFICATION OF FUNCTIONALLY IMPORTANT RESIDUES IN PROTEIN S FOR ITS INTERACTION WITH TFPI <i>Adrienn TERAZ-OROSZ, Salvatore Santamaria, James TB Crawley, David A Lane and Josefin Ahnström</i> Centre for Haematology, Faculty of Medicine, Imperial College London, London, UK
14:05 – 14:10	Discussion
14:10 – 14:20	Scientist in Training 2 ANTI-CUB AND ANTI-SPACER ANTIBODIES THAT CONFORMATIONALLY ACTIVATE ADAMTS13 WORK THROUGH ENHANCEMENT OF THE METALLOPROTEASE DOMAIN FUNCTION <i>Anastasis PETRI<sup>1</sup>, An-Sofie Schelpe<sup>2</sup>, Nele Vandeputte<sup>2</sup>, Hans Deckmyn<sup>2</sup>, Simon F De Meyer<sup>2</sup>, Karen Vanhoorelbeke<sup>2</sup>, James TB Crawley<sup>1</sup></i> <sup>1</sup> Centre for Haematology, Imperial College London, London, United Kingdom, <sup>2</sup> Laboratory for Thrombosis Research, KU Leuven, Kortrijk, BELGIUM
14:20 – 14:25	Discussion
14:25 – 14:35	Scientist in Training 3 NOVEL PLATELET-NEUTROPHIL INTERACTION VIA ACTIVATED $\alpha_{IIb}\beta_3$ MEDIATES NETOSIS UNDER FLOW <i>Adela CONSTANTINESCU-BERCU, Isabelle I. Salles-Crawley, Kevin J Woollard &amp; James T.B. Crawley</i> Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London, UK
14:35 – 14:40	Discussion
14:40 – 14:50	Scientist in Training 4 CANCER CELLS RELEASE ACTIVE TF-FVIIa COMPLEX WHICH CAN BE DIRECTLY INHIBITED BY APIXABAN <i>Yahya MADKHALI<sup>1</sup>, Sophie Featherby<sup>1</sup>, Anthony Maraveyas<sup>2</sup>, John Greenman<sup>1</sup>, Camille Ettelaie<sup>1</sup></i> <sup>1</sup> Biomedical Section, School of Life Sciences, University of Hull, Cottingham Road, Hull, HU6 7RX, UK., <sup>2</sup> Division of Cancer-Hull York Medical School, University of Hull, Cottingham Road, Hull, HU6 7RX, UK
14:50 – 14:55	Discussion
14:55 – 15:05	Scientist in Training 5 CROSS-TALK BETWEEN THE ALTERNATIVE PATHWAY OF COMPLEMENT AND THE INTRINSIC PATHWAY OF COAGULATION <i>Samantha L HEAL, Lewis J Hardy, Beth A Webb, Clare L Wilson, Helen Philippou</i> Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK
15:05 – 15:10	Discussion
15:10 – 15:40	Refreshments, networking + exhibition
15:40 – 17:45	<b>SESSION THREE: Plenary 3 and Emerging Fellows</b>
	<i>Co-chairs: Henry WATSON &amp; Rhona MACLEAN</i>
15:40 – 16:10	<b>New therapeutic options in the treatment of TTP</b> <i>Marie SCULLY</i> (London)
16:10 – 16:15	Discussion
	<b>Emerging Fellows</b>
16:15 – 16:35	<b>Procoagulant lipids. A future treatment for abdominal aortic aneurysms?</b> <i>Keith ALLEN-REDPATH</i> (Cardiff)
16:35 – 16:40	Discussion

16:40 – 17:00	<i>Learning how to restrain the world's most prolific killers (platelets)</i> <b>Mark THOMAS</b> (Birmingham)
17:00 – 17:05	Discussion
17:05 – 17:25	<i>Personalised prophylaxis in Haemophilia A: the population pharmacokinetic approach</i> <b>Saket BADLE</b> (London)
17:25 – 17:30	Discussion
17:30 – 17:50	<i>Regulation of clot stability by the serine/threonine phosphatase PP1</i> <b>Zoltan NAGY</b> (Birmingham)
17:50 – 17:55	Discussion
<b>17:55 – 19:15</b>	<b>Poster session + Drinks Reception</b>
<b>19:30</b>	<b>Conference Dinner</b> <i>Radcliffe House Dining Room (purchased ticket holders only)</i>

## PROGRAMME – Friday 9 November

07:00 – 08:00	Breakfast ( <i>Radcliffe House residents only</i> )	<i>Radcliffe Dining Room</i>
08:00 – 08:30	Registration, Refreshments + networking	<i>The Slate</i>
08:30 – 10:10	<b>SESSION FOUR: Plenary 4 and Oral Communications 3</b>	
	<i>Co-chairs: Catherine BAGOT &amp; Chris GARDINER</i>	
08:30 – 09:00	<b>Cancer and thrombosis</b> <b>Henry WATSON</b> (Aberdeen)	
09:00 – 09:05	Discussion	
09:05 – 09:15	Transfer time to parallel session	
	<p style="text-align: center;"><b>CLINICAL TRAINING SESSION (Parallel Session)</b> <span style="float: right;"><i>Radcliffe Space 1</i></span></p> <p style="text-align: center;"><i>Chair: Keith GOMEZ</i></p> <p style="text-align: center;">09:15 – 09:40 <b>Mike LAFFAN</b> (London)</p> <p style="text-align: center;"><b>Global haemostatic assays in clinical practice</b></p> <p style="text-align: center;">09:40 – 10:10 <b>Pratima CHOWDARY</b> (London)</p> <p style="text-align: center;"><b>Novel therapies for haemophilia</b></p>	
	<b>Oral Communications 2</b>	
09:10 – 09:20	<p>6 DISSIMILAR EFFECTS OF DIRECT ORAL ANTICOAGULANTS ON THE RELEASE OF TF-POSITIVE MICROVESICLES AND CANCER CELL PROLIFERATION</p> <p><i>Sophie FEATHERBY<sup>1</sup>, Yahya Madkhali<sup>2</sup>, Anthony Maraveyas<sup>2</sup>, Camille Ettelaie<sup>1</sup></i></p> <p><sup>1</sup>Biomedical Section, School of Life Sciences, University of Hull, Cottingham Road, Hull, HU6 7RX, UK., <sup>2</sup>Division of Cancer-Hull York Medical School, University of Hull, Cottingham Road, Hull, HU6 7RX, UK</p>	
09:20 – 09:25	Discussion	

09:25 – 09:35	7 MICRORNA-223 IN PLATELET-DERIVED EXTRACELLULAR VESICLES DOWNREGULATES TISSUE FACTOR EXPRESSION IN THP-1 MONOCYTIC CELLS <i>Mary E W COLLIER, Ashley R Ambrose, Alison H Goodall</i> Department of Cardiovascular Sciences, University of Leicester and NIHR Cardiovascular Biomedical Research Unit, Glenfield Hospital, Leicester LE3 9QP
09:35 – 09:40	Discussion
09:40 – 09:50	8 PREVALENCE OF ANTI-PROTEIN C ANTIBODIES AND ACQUIRED ACTIVATED PROTEIN C RESISTANCE IN SYSTEMIC LUPUS ERYTHEMATOSUS <i>Giuseppe A. Ramirez<sup>1, 2, 3</sup>, Hannah Cohen<sup>4, 5</sup>, Ian Mackie<sup>4</sup>, David Isenberg<sup>1, 2</sup>, Maria EFTHYMIQU<sup>4</sup></i> <sup>1</sup> Centre for Rheumatology, Division of Medicine, University College London, London, UK <sup>2</sup> Department of Rheumatology, University College London Hospitals NHS Foundation Trust, London, UK <sup>3</sup> Università Vita-Salute San Raffaele, Milan, Italy <sup>4</sup> Haemostasis Research Unit, Department of Haematology, University College London, London, UK <sup>5</sup> Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK
09:50 – 09:55	Discussion
09:55 – 10:05	9 PATIENTS WITH RECURRENT VENOUS THROMBOEMBOLISM HAVE LESS ELASTIC CLOTS THAN THOSE WITH NON-RECURRENT DISEASE <i>Stephen R. BAKER<sup>1</sup>, Michal Zabczyk<sup>2</sup>, Anetta Undas<sup>2</sup>, Robert A. S. Ariëns<sup>1</sup></i> <sup>1</sup> Theme Thrombosis, Department of Discovery and Translational Science, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, UK. ~ <sup>2</sup> Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland and John Paul II Hospital, Krakow, POLAND
10:05 – 10:10	Discussion
10:10 – 10:40	Refreshments, Refreshments + networking <span style="float: right;"><i>The Slate</i></span>
	<div style="border: 2px solid blue; padding: 10px; background-color: #fff9c4;"> <p><b>CLINICAL TRAINING SESSION (Parallel Session)</b> <span style="float: right;"><i>Radcliffe Space 1</i></span></p> <p><i>Chair: Keith GOMEZ</i></p> <p>10:40 – 11:10 <b>Rhona MACLEAN</b> (Sheffield)</p> <p><b>When &amp; how to thrombolysate in venous thrombosis</b></p> <p>11:10 – 11:35 <b>Keith GOMEZ</b> (London)</p> <p><b>Genomics in the haemostasis clinic</b></p> </div>
10:40 – 12:30	<b>SESSION FIVE: Plenary 5 &amp; Oral Communications 3</b>
	<i>Co-chairs: Nikki MUTCH &amp; Isabelle SALLES-CRAWLEY</i>
10:40 – 10:50	10 ERP44, A NEW THIOL ISOMERASE ENZYME THAT IS PRESENT IN PLATELETS <i>Shurug ALSUFYANI, Lisa-Marie Holbrook, Jonathan M Gibbins</i> Institute for Cardiovascular and Metabolic Research, School of Biological Sciences, University of Reading, Harborne Building, Whiteknights, Reading, Berkshire, RG6 6AS, UK
10:50 – 10:55	Discussion
10:55 – 11:05	11 CHARACTERISATION OF A GENETICALLY MODIFIED FXIII-A L34V MODEL AND POTENTIAL FOR VASCULAR STUDIES <i>Adomas BARANAUSKAS, Robert A.S. Ariëns, Cédric Duval</i> Discovery and Translational Science Department, Leeds Institute of Cardiovascular And Metabolic Medicine, The LIGHT Laboratories, University of Leeds, Clarendon Way, LS2 9NL, UK
11:05 – 11:10	Discussion
11:10 – 11:20	12 BTK INHIBITION INHIBITS CLEC-2 MEDIATED PLATELET ACTIVATION <i>Joshua HINDS<sup>1</sup>, Stephanie K Watson<sup>1</sup>, Guy Pratt<sup>2</sup>, Phillip LR Nicolson<sup>1</sup></i> <sup>1</sup> Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK <sup>2</sup> Department of Haematology, Queen Elizabeth Hospital, Birmingham, B15 2TH, UK
11:20 – 11:25	Discussion

11:25 – 11:35	13 INCIDENCE OF THROMBOCYTOPENIA AND HEPARIN INDUCED THROMBOCYTOPENIA IN PATIENTS RECEIVING EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) COMPARED TO CARDIOPULMONARY BYPASS (CPB) AND THE LIMITED SENSITIVITY OF PRE-TEST PROBABILITY SCORE <i>Deepa RJ ARACHCHILLAGE</i> <sup>1,2,3</sup> , <i>Sanjay Khanna</i> <sup>1</sup> , <i>Christophe Vandenbrielle</i> <sup>1</sup> , <i>Jonathan Dutton</i> <sup>1</sup> , <i>Alex Rosenberg</i> <sup>1</sup> , <i>TV Aw</i> <sup>2</sup> , <i>Winston Banya</i> <sup>1</sup> , <i>Mike Laffan</i> <sup>2,3</sup> , <i>Stephane Ledot</i> <sup>1</sup> , <i>Brijesh Patel</i> <sup>1,3</sup> <sup>1</sup> Royal Brompton & Harefield NHS Foundation Trust, London, UK <sup>2</sup> Imperial College Healthcare NHS Trust, London, UK <sup>3</sup> Imperial College London, London, UK
11:35 – 11:40	Discussion
<b>Summer Student Presentations</b>	
11:40 – 11:45	Summer Student 1 THE DEVELOPMENT OF IMPROVED BIO-ENGINEERED EXPRESSION CASSETTES FOR GENE THERAPY OF HAEMOPHILIA A <i>Ellie HOLDEN</i>
11:45 – 11:50	Summer Student 2 NEUTRALISATION OF EXTRACELLULAR HISTONES TO PROMOTE FIBRINOLYSIS AND REDUCE HISTONE CYTOTOXICITY <i>Evgenia TSAOUI</i>
11:50 – 11:55	Summer Student 3 STRUCTURAL BASIS OF THE LEUKOCYTE INTEGRIN MAC-1 I-DOMAIN INTERACTION WITH THE PLATELET GP1B $\alpha$ N-TERMINAL DOMAIN <i>Ruiqi NG</i>
<b>Plenary 5</b>	
11:55 – 12:25	<b><i>Mechanisms of thrombus formation in mice</i></b> <i>Christophe DUBOIS</i> (France)
12:25 – 12:30	Discussion
12:30 – 13:30	<b>BSHT AGM &amp; Lunch, networking + exhibition</b>
13:30 – 15:20	<b>SESSION SIX: Plenary 6 &amp; Oral Communications 4</b>
<i>Co-Chairs: Jim CRAWLEY &amp; Keith GOMEZ</i>	
13:30 – 14:00	<b><i>Modifying serpin specificity to therapeutic effect: The creation of SerpinPC, a pan-haemophilia agent</i></b> <i>Jim HUNTINGTON</i> (Cambridge)
14:00 – 14:05	Discussion
<b>Oral Communications 4</b>	
14:05 – 14:15	14 A PRACTICAL METHOD FOR REDUCING INTERFERENCE BY LIPAEMIA FOR COAGULATION TESTS <i>Chris GARDINER</i> , <i>Philip Lane</i> , <i>Ian J Mackie</i> Haemostasis Research Unit, 1 <sup>st</sup> Floor, 51 Chenies Mews, University College London, London WC1E 6HX
14:15 – 14:20	Discussion
14:20 – 14:30	15 PARTIAL RESCUE OF NATURALLY OCCURRING ACTIVE SITE FACTOR X VARIANTS THROUGH DECREASED INHIBITION BY TFPI AND ANTITHROMBIN <i>Josefin AHNSTRÖM</i> , <i>Joseph Temenu</i> , <i>Michael A. Laffan</i> and <i>David A. Lane</i> Centre for Haematology, Faculty of Medicine, Imperial College London, London, UK
14:30 – 14:35	Discussion
14:35 – 14:45	16 ASSESSING THE IMPACT OF NICE GUIDELINE NG89 ON HOSPITALISED MEDICAL PATIENTS AT RISK OF VENOUS THROMBOEMBOLISM <i>Will LESTER</i> <sup>1</sup> , <i>Keval Dabhi</i> <sup>2</sup> and <i>Deepak Chandra</i> <sup>3</sup> Centre for Clinical Haematology, University Hospitals Birmingham, Edgbaston, Birmingham, B15 2TH Health Informatics department, Yardley Court, Edgbaston, Birmingham, B15 1JD Department of Clinical Haematology, Royal Stoke University Hospital, University Hospitals of North Midlands NHS Trust, ST4 6QG
14:45 – 14:50	Discussion
14:50 – 15:00	17 THE CRITICAL ROLE OF TISSUE FACTOR PATHWAY INHIBITOR (TFPI) UNDER FLOW AND <i>IN VIVO</i> <i>Isabelle I. SALLES-CRAWLEY</i> *, <i>Josefin Ahnström</i> * & <i>James TB Crawley</i> * Centre for Haematology, Hammersmith Hospital Campus, Imperial College London, London, UK

15:00 – 15:05	Discussion
15:05 – 15:15	18 ANTIBODY-MEDIATED CLEARANCE OF ADAMTS13 IN ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA: A ROLE FOR MONOCYTES? <i>Mary I UNDERWOOD</i> 1, <i>Mari R Thomas</i> 2, <i>Marie A Scully</i> 2, <i>James TB Crawley</i> 1 1 Centre for Haematology, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London W12 0NN, UK 2 Department of Haematology University College Hospital, London NW1 2BU, UK
15:15 – 15:20	Discussion
	<b>Meeting Close</b>

## POSTERS

P-1

DESIGN AND ANALYSIS OF SMALL COMPOUNDS TO RESTRAIN THE FUNCTIONS OF TISSUE FACTOR WITHIN TUMOUR CELLS

*Oluremi I Adeniran*<sup>1</sup>, *Mohammad A Mohammad*<sup>2</sup>, *Anthony Maraveyas*<sup>3</sup>, *Andrew N Boa*<sup>1</sup>, *Camille Ettelaie*<sup>2</sup>

<sup>1</sup>Chemistry Section, School of Mathematics and Physical Sciences, University of Hull, Cottingham Road, Hull, HU6 7RX, UK., <sup>2</sup>Biomedical Section, School of Life Sciences, University of Hull, Cottingham Road, Hull, HU6 7RX, UK., <sup>3</sup>Division of Cancer-Hull York Medical School, University of Hull, Cottingham Road, Hull, HU6 7RX, UK

P-2

IDENTIFICATION AND FUNCTIONAL INVESTIGATION OF GENES IN PATIENTS WITH INHERITED BLEEDING DISORDERS

*Ibrahim Almazni*

Institute of Cardiovascular Science, University of Birmingham, Edgbaston, B15 2TT, Birmingham, UK.

P-3

CORRELATION BETWEEN ELISAS AND AUTOMATED CHEMILUMINESCENCE PANELS TO DETECT ANTI-BETA2-GLYCOPROTEIN I ANTIBODIES IN LABORATORY DIAGNOSIS OF ANTIPHOSPHOLIPID SYNDROME

*Neha Thomas*<sup>1</sup>, *Kurtis Lee*<sup>1</sup>, *Richard Szydlo*<sup>2</sup>, *Mike Laffan*<sup>1</sup>, *Deepta RJ Arachchillage*<sup>1,2</sup>

<sup>1</sup>Imperial College Healthcare NHS Trust, London, UK

<sup>2</sup>Imperial College London, London, UK

P-4

AN EVIDENCE REVIEW TO DETERMINE THE EFFICACY OF NOVEL ORAL ANTICOAGULANTS (NOACS) COMPARED TO WARFARIN AT REDUCING VENOUS THROMBOEMBOLISM RECURRENCE IN ADULT PATIENTS

*Arebi M*<sup>1</sup>, *Baker D*<sup>1</sup>, *Marshall T*<sup>2</sup>.

<sup>1</sup>College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.

<sup>2</sup>Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK.

P-5

ALTERATIONS IN ENDOTHELIAL PERMEABILITY OCCURS IN RESPONSE TO THE ACTIVATION OF PAR2 BY FACTOR Xa BUT NOT BY TF-FACTOR VIIa

*Naima E. Benelhaj*<sup>1</sup>, *Anthony Maraveyas*<sup>1</sup>, *Sophie Featherby*<sup>2</sup>, *Miriam J Johnson*<sup>1</sup>, *Camille Ettelaie*<sup>2</sup>

<sup>1</sup>Division of Cancer-Hull York Medical School, University of Hull, Cottingham Road, Hull, HU6 7RX, UK, <sup>2</sup>Biomedical Section, School of Life Sciences, University of Hull, Cottingham Road, Hull, HU6 7RX, UK.

P-6

EFFECTS OF WEIBEL-PALADE BODY PLASTICITY ON VWF FUNCTIONING.

*Francesco Ferraro*, *Mafalda Lopes da Silva*, *Jessica McCormack*, *Ian White*, *Jemima Burden*, *Kimberley Harrison-Lavoie*, *Daniel Cutler*

MRC laboratory for Molecular Cell Biology, UCL, Gower St, London WC1E 6BT

P-7

LOW MOLECULAR WEIGHT HEPARIN REDUCES TUMOUR FORMATION, INVASION AND VASCULARISATION

*Sophie Featherby*<sup>1</sup>, *Camille Ettelaie*<sup>1</sup>, *John Greenman*<sup>1</sup>, *Anthony Maraveyas*<sup>2</sup>

<sup>1</sup>Biomedical Section, School of Life Sciences, University of Hull, Cottingham Road, Hull, HU6 7RX, UK., <sup>2</sup>Division of Cancer-Hull York Medical School, University of Hull, Cottingham Road, Hull, HU6 7RX, UK

P-8

VARIATIONS IN BINDING OF GPVI VARIANTS TO DIFFERENT FIBRIN(OGEN) FRAGMENTS

*Julia S. Gauer*<sup>1</sup>, *Rui-gang Xu*<sup>1</sup>, *Alexandre Slater*<sup>2</sup>, *Gina Parrella*<sup>2</sup>, *Marie-Blanche Onselaer*<sup>2</sup>, *Cédric Duval*<sup>1</sup>, *Andrew Herr*<sup>3</sup>, *Steve P. Watson*<sup>2</sup>, *Robert A. S. Ariëns*<sup>1</sup>

<sup>1</sup>Discovery and Translational Science Department, Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, LS2 9LU, UK.

<sup>2</sup>Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK.

<sup>3</sup>Department of Molecular Genetics, Biochemistry & Microbiology, University of Cincinnati College of Medicine, 231 Albert Sabin Way, OH 45267-0524, USA

P-9

THE PROTHROMBOTIC PHENOTYPE INDUCED BY NILOTINIB AND PONATINIB TYROSINE KINASE INHIBITORS IS REVERSED BY BLOCKADE OF CALCIUM FLUX

*Abdullah Hamadi*<sup>1</sup>, *Faith A. Kwa*<sup>1</sup>, *Kate L. Burbury*<sup>2</sup>, *Andrew P. Grigg*<sup>3</sup> and *Denise E Jackson*<sup>1</sup>

<sup>1</sup>Thrombosis and Vascular Diseases Laboratory, School of Health and Biomedical Sciences, RMIT University, Bundoora. Victoria. Australia;  
<sup>2</sup>Haematology Department, Peter MacCallum Cancer Centre, Parkville. Australia; <sup>3</sup>Department of Haematology, Austin Health, Heidelberg. Victoria. Australia.

P-10

INVESTIGATION OF MECHANISM OF TISSUE FACTOR-MEDIATED CELL APOPTOSIS

*Yahya Madkhali<sup>1</sup>, John Greenman<sup>1</sup>, Anthony Maraveyas<sup>2</sup>, Camille Ettelaie<sup>1</sup>*

<sup>1</sup>Biomedical Section, School of Life Sciences, University of Hull, Cottingham Road, Hull, HU6 7RX, UK., <sup>2</sup>Division of Cancer-Hull York Medical School, University of Hull, Cottingham Road, Hull, HU6 7RX, UK

P-11

THE CELLULAR LOCATION OF TISSUE FACTOR IS CONSTRAINED BY MAGI-1 AND IS RELEASED BY PAR2 ACTIVATION

*Mohammad A Mohammad<sup>1</sup>, Mary E Collier<sup>2</sup>, Anthony Maraveyas<sup>3</sup>, John Greenman<sup>1</sup>, Camille Ettelaie<sup>2</sup>*

<sup>1</sup>Biomedical Section, School of Life Sciences, University of Hull, Cottingham Road, Hull, HU6 7RX, UK., <sup>2</sup>Department of Cardiovascular Sciences, University of Leicester, Clinical Sciences Wing, Glenfield General Hospital, Leicester, LE3 9QP, <sup>3</sup>Division of Cancer-Hull York Medical School, University of Hull, Cottingham Road, Hull, HU6 7RX, UK

P-12

LONG TERM EXPOSURE TO TISSUE FACTOR INDUCE CELL PROLIFERATION BY LOWERING PTEN PROTEIN LEVELS

*Mohammad A Mohammad<sup>1</sup>, John Greenman<sup>1</sup>, Anthony Maraveyas<sup>2</sup>, Camille Ettelaie<sup>1</sup>*

<sup>1</sup>Biomedical Section, School of Life Sciences, University of Hull, Cottingham Road, Hull, HU6 7RX, UK., <sup>2</sup>Division of Cancer-Hull York Medical School, University of Hull, Cottingham Road, Hull, HU6 7RX, UK

P-13

CLINICAL MANAGEMENT OF AUTOIMMUNE ACQUIRED FACTOR XIII DEFICIENCY DURING PREGNANCY

*Delia Dima<sup>1</sup>, Ioana Rus<sup>1</sup>, Sergiu Pasca<sup>1</sup>, Ioana Felea<sup>2</sup>, Mariana Chitic<sup>1</sup>, Mihai Muresan<sup>3</sup>, Cosmin Lisencu<sup>3</sup>, Alexandru Irimie<sup>3</sup>, Mihnea Zdrenghia<sup>1</sup>, Ciprian Tomuleasa<sup>1,4</sup>.*

<sup>1</sup> Department of Hematology, Ion Chiricuta Oncology Institute, Cluj Napoca, Romania.;

<sup>2</sup> Department of Rheumatology, Emergency Clinical Hospital, Cluj Napoca, Romania.;

<sup>3</sup> Department of Surgery, Ion Chiricuta Oncology Institute, Cluj Napoca, Romania.;

<sup>4</sup> Research Center for Functional Genomics and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania

P-14

ORAL SURGERY FOR COMBINED HAEMOPHILIA A AND B. THE DOS AND DON'TS PRESENTED IN A CLINICAL SCENARIO

*Madalina A Lazar<sup>1</sup>, Ovidiu Muresan<sup>2</sup>, Calin R Roman<sup>2</sup>, Delia Dima<sup>3</sup>, Sergiu Pasca<sup>3</sup>, Mihai Stefan Muresan<sup>4</sup>, Gabriel Armentea<sup>2</sup>, Ciprian Tomuleasa<sup>3</sup>, Horatiu Rotaru<sup>2</sup>.*

<sup>1</sup> Department of Implantology and Maxillofacial Surgery, Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca, Romania.;

<sup>2</sup> Department of Oral and Maxillofacial Surgery, Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca, Romania

<sup>3</sup> Department of Hematology, Ion Chiricuta Clinical Research Center, Cluj Napoca, Romania

<sup>4</sup> Department of Surgery, Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca, Romania

P-15

DIETARY ZINC INATKE MODULATES PLATELET AGGREGATION, CLOT FORMATION AND FIBRINOLYSIS

*U Sumya, J Beattie, NJ Mutch*

School of Medicine, Medical Sciences and Nutrition, Institute of Medical Sciences, Foresterhill, Aberdeen, AB25 2ZD

The Rowett Institute, Foresterhill, Aberdeen, AB25 2ZD

P-16

LARGE-SCALE SCREENING FOR MEMBRANE PROTEIN INTERACTIONS INVOLVED IN PLATELET-MONOCYTE INTERACTIONS

*Yi Sun<sup>1</sup>, George Ed Rainger<sup>1</sup> & Steve P Watson<sup>1</sup>*

<sup>1</sup> Institute of Cardiovascular Science, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham. B15 2TT

P-17

ONE-STEP PURIFICATION OF FIBRIN(OGEN) FRAGMENTS AND THEIR BINDINGS TO GPVI IN SOLUTION

*Rui-Gang Xu<sup>1</sup>, Julia S. Gauer<sup>1</sup>, Alexandre Slater<sup>2</sup>, Gina Parrella<sup>2</sup>, Marie-Blanche Onselae<sup>1</sup>, Cedric Duval<sup>1</sup>, Iain Manfield<sup>3</sup>, Chi Trinh<sup>4</sup>, Andrew Herr<sup>5</sup>, Steve P. Watson<sup>2</sup>, Robert A. S. Ariens<sup>1</sup>*

<sup>1</sup> Discovery and Translational Science Department, Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, LS2 9LU, UK.

<sup>2</sup> Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK

<sup>3</sup> School of Molecular and Cellular Biology, Faculty of biological sciences, University of Leeds, Leeds, LS2 9LU, UK.

<sup>4</sup> The Astbury Centre for Structural Molecular Biology, Faculty of biological sciences, University of Leeds, Leeds, LS2 9LU, UK.

<sup>5</sup> Department of Molecular Genetics, Biochemistry & Microbiology, University of Cincinnati College of Medicine, 231 Albert Sabin Way, OH 45267-0524, USA